NeuroMetrix, Inc. (NURO)
| Market Cap | 9.43M +27.3% |
| Revenue (ttm) | 3.03M -48.6% |
| Net Income | -7.81M |
| EPS | -3.96 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 30,307 |
| Open | 4.360 |
| Previous Close | 4.580 |
| Day's Range | 4.360 - 4.580 |
| 52-Week Range | 2.660 - 4.730 |
| Beta | 1.84 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 14, 2025 |
About NURO
NeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing and sale of medical devices. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; and Quell, a wearable device for symptomatic relief and management of chronic pain. The company offers its products to managed endocrinologists, podiatrists, primary care physicians, and other clinicians at the point-of care to objectively detect, stage, and monitor peripheral neuro... [Read more]
Financial Performance
In 2024, NeuroMetrix's revenue was $3.03 million, a decrease of -48.61% compared to the previous year's $5.90 million. Losses were -$7.81 million, 19.6% more than in 2023.
Financial StatementsNews
NEUROMETRIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of NeuroMetrix, Inc. - NURO
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of NeuroMetrix, Inc...
NeuroMetrix to be Acquired by electroCore
WOBURN, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (“NeuroMetrix” or the “Company”) (Nasdaq: NURO) today announced it has entered into a definitive merger agreement whereby electroCore...
NeuroMetrix Reiterates its Review of Strategic Alternatives
WOBURN, Mass., Aug. 13, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today for the purpose of clarity, reiterated that the Company is engaged in a review of strategic alternatives.
NeuroMetrix, Inc. Announces Date for Second Quarter 2024 Business Highlights Conference Call
WOBURN, Mass., July 31, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2024 second quarter business and financial highlights before the opening of...
NeuroMetrix Reports Q1 2024 Business Highlights
WOBURN, Mass., May 15, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended March 31, 2024.
NeuroMetrix Announces Steps Taken to Enhance Shareholder Value
Joshua S. Horowitz joins Board of Directors At-the-market equity facility terminated WOBURN, Mass., April 19, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ: NURO) today announced two steps to enh...
NeuroMetrix Announces Publication of Study Demonstrating that DPNCheck Accurately Diagnoses Diabetic Peripheral Neuropathy
WOBURN, Mass., March 14, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) noted the recent publication of a large study demonstrating that DPNCheck® combined with standard EKG or DPNCheck alo...
NeuroMetrix announces that over 2000 patients with fibromyalgia have been prescribed Quell® Fibromyalgia
NeuroMetrix today announced that over 2000 fibromyalgia patients have been prescribed Quell Fibromyalgia since its strategic commercial launch in Dec 2022.
Echo Lake Capital Issues Top Ten List of Reasons Why Shai Gozani, CEO of Neurometrix Inc., Should Be Fired
NURO stock price has declined 99% since its IPO Gozani has received compensation of over $10 million since the IPO Gozani was charged by the FTC for various wrongdoings at NURO Gozani apparently perso...
Echo Lake Capital Calls for the Liquidation of Neurometrix, Inc.
- Stock trades significantly below its net cash per share - Questions the Board's ability and/or desire to create shareholder value - Notes tremendous destruction of shareholder value under company's ...
NeuroMetrix Reports Q4 and Full Year 2023 Business Highlights
WOBURN, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and full year ended December 31, 2023.
NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2023 Business Highlights Conference Call
NeuroMetrix plans to issue its 2023 fourth quarter and year end business and financial highlights before the opening of the market on February 22, 2024.
NeuroMetrix Announces Review of Strategic Options to Promote Growth and Maximize Shareholder Value
WOBURN, Mass., Feb. 13, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO), a commercial stage medical device company focused on reducing the impact of neurological disorders and pain syndromes...
NeuroMetrix to Present at the Emerging Growth Conference on January 10, 2024
NeuroMetrix announced today that the Company's Chairman and CEO, Dr. Shai N. Gozani will present at the Emerging Growth Conference on January 10, 2024.
NeuroMetrix Reports Encouraging Results from Pilot Clinical Trial of Quell® in Post-Acute COVID-19 Syndrome (Long COVID)
WOBURN, Mass., Dec. 12, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) reported the recent presentation of data from a clinical trial of Quell wearable neuromodulation technology in patient...
NeuroMetrix Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Showing that Quell® Improves Painful Symptoms of Chemotherapy Induced Peripheral Neuropathy (CIPN)
NeuroMetrix noted publication of results from a NIH-funded clinical trial of Quell. The paper has been electronically published in The Journal of Pain.
NeuroMetrix Announces One-for-Eight Reverse Stock Split
WOBURN, Mass., Nov. 20, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ: NURO) today announced that it will effect a one-for-eight reverse split of its common stock, effective at 5:00 pm on Novembe...
NeuroMetrix to Present at the Emerging Growth Conference on November 1, 2023
WOBURN, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO), announced today that it will present at the Emerging Growth Conference on Wednesday, November 1, 2023.
NeuroMetrix Reports Q3 2023 Business Highlights
WOBURN, Mass., Oct. 26, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported business and financial highlights for the quarter and nine month period ended September 30, 2023.
NeuroMetrix, Inc. Announces Date for Third Quarter 2023 Business and Financial Highlights Conference Call
NeuroMetrix, Inc. announced today that it plans to issue its Q3 2023 business and financial highlights on October 26, 2023 at 8:00 a.m., Eastern Time.
NeuroMetrix and the National Fibromyalgia Association to Collaborate to Improve the Quality of Life for People Living with Fibromyalgia
WOBURN, Mass., Oct. 02, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ: NURO) announced that it has been selected as a Proud Sponsor of the National Fibromyalgia Association (NFA).
NeuroMetrix to Present at the Emerging Growth Conference on October 4, 2023
WOBURN, Mass., Sept. 28, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO), announced today that it will present at the Emerging Growth Conference on October 4, 2023.
NeuroMetrix to Present at the Emerging Growth Conference on September 6, 2023
WOBURN, Mass., Aug. 30, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO), announced today that it will present at the Emerging Growth Conference on September 6, 2023. This live, interactive, ...
NeuroMetrix Reports Q2 2023 Business Highlights
WOBURN, Mass., July 27, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported business and financial highlights for the quarter and six months period ended June 30, 2023. The Compan...
NeuroMetrix, Inc. Announces Date for Second Quarter 2023 Business and Financial Highlights Conference Call
WOBURN, Mass., July 20, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its Q2 2023 business and financial highlights before the opening of the market ...